Recursion Pharmaceuticals RXRX
$2.45 −$0.27 (-9.93%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $2.51 +2.39%
Open$2.63
Prev close$2.72
Day range$2.44 – $2.76
Volume29.88M
Market cap$1.53B
P/E (TTM)–
Dividend yield–
Earnings
Average move on report day±5.2%last 12 reports
Closed higher3 of 1225% of the time
Best reaction+6.8%
Worst reaction-16.6%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q3 | 2 Nov 2026 | After Market | ±10.9% | -3.92% | Within range |
| 2026/Q2 | 5 Aug 2026 | Pre Market | ±8.1% | -4.23% | Within range |
| 2026/Q1 | 6 May 2026 | Pre Market | ±8.1% | +1.78% | Within range |
| 2025/Q4 | 25 Feb 2026 | Pre Market | ±7.6% | +6.80% | Within range |
| 2025/Q3 | 5 Nov 2025 | Pre Market | ±10.6% | -0.80% | Within range |
| 2025/Q2 | 5 Aug 2025 | Pre Market | ±13.9% | -4.66% | Within range |
| 2025/Q1 | 5 May 2025 | Pre Market | ±16.8% | -16.58% | Within range |
| 2024/Q4 | 28 Feb 2025 | Pre Market | ±16.0% | -2.09% | Within range |
| 2024/Q3 | 6 Nov 2024 | After Market | ±14.5% | -0.57% | Within range |
| 2024/Q2 | 8 Aug 2024 | Pre Market | ±22.8% | +4.24% | Within range |
| 2024/Q1 | 9 May 2024 | After Market | ±13.8% | -0.46% | Within range |
| 2023/Q4 | 27 Feb 2024 | After Market | ±26.2% | -16.62% | Within range |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$18.06M+262.3% YoY
Operating profit-$123.18M+28.5% YoY
Net profit-$119.04M+26.6% YoY
Diluted EPS-$0.22+38.9% YoY
Free cash flow-$77.81M+33.8% YoY
Operating cash flow-$77.41M
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin27.9%
Operating margin-738.7%
Net margin-709.8%
Return on equity-48.7%
Return on assets-36.3%
Return on invested capital-47.1%
Current ratio5.01
Liabilities / assets25.9%
Cash & investments$549.85M
Total debt$62.44M
Net cash (debt)$487.42M
No comments yet — be the first to weigh in on RXRX.
Sign in to join the discussion.